Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sanofi
Biotech
Sanofi's $80M bet on Fulcrum dystrophy drug ends in phase 3 fail
Just four months after Sanofi bet $80 million upfront on Fulcrum Therapeutics’ losmapimod, the program has ended in a phase 3 failure.
James Waldron
Sep 12, 2024 9:30am
Sanofi pays $110M upfront for late-stage radioligand therapy
Sep 12, 2024 4:54am
Sanofi's tolebrutinib fails 2 of 3 late-stage MS trials
Sep 2, 2024 1:00am
Vir gains 3 T-cell engagers from Sanofi, lays off 25% of staff
Aug 2, 2024 6:12am
Sanofi will drop dwarfism drug as part of rare disease clear-out
Jul 25, 2024 7:58am
AI-focused Formation bags $372M series D to license more drugs
Jun 26, 2024 10:05am